{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "priceEpsCurrentYear": -0.23529412, "sharesOutstanding": 8423500, "bookValue": 3.236, "fiftyDayAverage": 2.6008, "fiftyDayAverageChange": -1.2008001, "fiftyDayAverageChangePercent": -0.4617041, "twoHundredDayAverage": 5.54285, "twoHundredDayAverageChange": -4.14285, "twoHundredDayAverageChangePercent": -0.74742234, "marketCap": 15802500, "forwardPE": -0.6422018, "priceToBook": 0.43263286, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Idera Pharmaceuticals, Inc.", "nameChangeDate": "2023-05-15", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "exchange": "NCM", "shortName": "Aceragen, Inc.", "longName": "Aceragen, Inc.", "messageBoardId": "finmb_29643", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": -6.6666684, "regularMarketPrice": 1.4, "firstTradeDateMilliseconds": 822580200000, "priceHint": 4, "regularMarketChange": -0.100000024, "regularMarketTime": 1684180804, "regularMarketDayHigh": 1.55, "regularMarketDayRange": "1.38 - 1.55", "regularMarketDayLow": 1.38, "regularMarketVolume": 152203, "regularMarketPreviousClose": 1.5, "bid": 0.0, "ask": 0.0, "bidSize": 11, "askSize": 9, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.5, "averageDailyVolume3Month": 308946, "averageDailyVolume10Day": 1769620, "fiftyTwoWeekLowChange": 0.01999998, "fiftyTwoWeekLowChangePercent": 0.01449274, "fiftyTwoWeekRange": "1.38 - 16.0", "fiftyTwoWeekHighChange": -14.6, "fiftyTwoWeekHighChangePercent": -0.9125, "fiftyTwoWeekLow": 1.38, "fiftyTwoWeekHigh": 16.0, "dividendDate": 1532908800, "earningsTimestamp": 1681416000, "earningsTimestampStart": 1684268100, "earningsTimestampEnd": 1684354500, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -6.3, "epsForward": -2.18, "epsCurrentYear": -5.95, "displayName": "Aceragen", "symbol": "ACGN"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "505 Eagleview Boulevard", "address2": "Suite 212", "city": "Exton", "state": "PA", "zip": "19341", "country": "United States", "phone": "(484) 348-1600", "website": "https://www.aceragen.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.", "fullTimeEmployees": 26, "companyOfficers": [{"maxAge": 1, "name": "Mr. John C. Taylor", "age": 51, "title": "Pres, CEO & Director", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 444062, "fmt": "444.06k", "longFmt": "444,062"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel  Salain", "age": 54, "title": "Chief Operating Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Gwen  Thomas", "title": "Associate Director of HR, Fin. & Admin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Christina  Amendola", "title": "Director of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew R. Jordan CPA, MBA", "age": 74, "title": "Chief Strategy Officer", "yearBorn": 1948, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Carl  Kraus M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Brian  Jackey", "title": "Sr. VP of Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Deepa  Nagpal", "title": "Global Head of Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Shah  Rahimian M.D., Ph.D.", "title": "Medical Director & Global Clinical Lead for Oncology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Joanna Caroline Horobin Ch.B, M.B.", "age": 67, "title": "Advisor", "yearBorn": 1955, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}